Slingshot Insights | Chrs Overview

CHRS Overview

Upcoming Projects (CHRS)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (CHRS)

Discussing Coherus' POLARIS-02 and JUPITER-02 studies and the potential of LOQTORZI (toripalimab-tpzi) in nasopharyngeal carcinoma
Ticker: CHRS
Executed On: Mar 05, 2024 at 03:00 PM EST
Getting a prescriber's take on Coherus' Cimerli and where biosimilars fit into the wet-AMD treatment landscape
Tickers: CHRS, RHHBY
Executed On: Dec 01, 2023 at 11:30 AM EST
Examining Coherus' Udenyca, the FDA-approved pegfilgrastim biosimilar prefilled autoinjector administered the day after chemotherapy to lower the risk of infection
Ticker: CHRS
Executed On: Apr 06, 2023 at 11:00 AM EDT
A Second look: Discussing the commercial outlook of Coherus' Cimerli (ranibizumab biosimilar) and Outlook's Lytenava (ophthalmic formulation of bevacizumab) in Wet AMD
Tickers: CHRS, OTLK
Executed On: Mar 15, 2023 at 03:00 PM EDT
Discussing the commercial outlook of Coherus' Cimerli (ranibizumab biosimilar) and Outlook's Lytenava (ophthalmic formulation of bevacizumab) in Wet AMD
Tickers: CHRS, OTLK
Executed On: Mar 14, 2023 at 03:00 PM EDT
Examining Coherus' Toripalimab in Nasopharyngeal Carcinoma before the April 29th PDUFA
Ticker: CHRS
Executed On: Apr 26, 2022 at 02:30 PM EDT
A look at the upcoming PDUFA of Toripalimab and the potential in nasopharyngeal carcinoma (NPC).
Ticker: CHRS
Executed On: Mar 18, 2022 at 02:00 PM EDT

Expired Projects (CHRS)

Comparing Coherus' Cimerli anti-VEGF with Lucentis in treating Wet AMD
Tickers: CHRS, RHHBY
Execute By: Sep 08, 2022

Upcoming & Overdue Catalysts (CHRS)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (CHRS)

U.S. Patent Office's Patent Trial and Appeal Board (PTAB) Denies Coherus (CHRS) Petition for Inter Partes Review of AbbVie's (ABBV) U.S. Patent No. 9,114,166 for HUMIRA
Tickers: CHRS, ABBV
Occurred on: Nov 07, 2016
Coherus has indicated that it expects to file its CHS-1701 Biologics License Application (BLA) in the second quarter of 2016
Ticker: CHRS
Occurred on: Aug 09, 2016
Phase 3 data of CHS-0214 for Rheumatoid arthritis due 1Q 2016
Ticker: CHRS
Occurred on: Jun 10, 2016
Coherus and Baxalta announce that a Phase 3 clinical trial comparing their biosimilar candidate to Amgen's Enbrel (etanercept), CHS-0214, in patients with rheumatoid arthritis met its primary endpoint of demonstrating equivalence
Tickers: CHRS, BXLT
Occurred on: Jan 11, 2016

Strategic Initiatives (CHRS)

Don’t see a strategic initiative related to the company you care about? Create your own!